1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol has been researched along with EHS Tumor in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 8 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, GE; Cole, S; Fielden, EM; Naylor, MA; O'Neill, P; Stephens, MA; Stratford, IJ; Threadgill, MD; Webb, P | 1 |
| Maddison, K; Siemann, DW; Wolf, K | 1 |
| Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ | 1 |
| Siemann, DW; Sutherland, RM | 1 |
| Adams, GE; Cole, S; Elliott, W; Fielden, EM; Leopold, W; Sebolt-Leopold, J; Stratford, IJ; Suto, M | 1 |
| Binger, M; Workman, P | 1 |
| Adams, GE; Bowler, J; Cole, S; Lorimore, SA; Nolan, J; Stratford, IJ; Wright, EG | 1 |
| Adams, GE; Bowler, J; Bremner, JC; Stratford, IJ | 1 |
| Adams, GE; Cole, S; Fielden, EM; Jenkins, TC; Stratford, IJ | 1 |
| Deacon, J; Holliday, S; Stratford, IJ; Walling, JM | 1 |
| Gulyas, S; Hill, RP; Whitmore, GF | 1 |
| Workman, P | 1 |
12 other study(ies) available for 1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol and EHS Tumor
| Article | Year |
|---|---|
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Mice; Nitro Compounds; Radiation-Sensitizing Agents; Sarcoma, Experimental; Structure-Activity Relationship; Thiophenes | 1991 |
Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069.
Topics: Animals; Aziridines; Azirines; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Melphalan; Mice; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental; Time Factors | 1984 |
Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Topics: Animals; Antineoplastic Agents; Mice; Mice, Inbred C3H; Misonidazole; Mitomycin; Nitroimidazoles; Photochemotherapy; Sarcoma, Experimental | 1994 |
Potentiation of alkylating chemotherapy by dual function nitrofurans in multi-cell spheroids and solid tumors.
Topics: Animals; Antineoplastic Agents; Aziridines; Bone Marrow; Carcinoma; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Lomustine; Mice; Mice, Inbred C3H; Mice, Inbred Strains; Misonidazole; Nitrofurans; Radiation-Sensitizing Agents; Sarcoma, Experimental; Stem Cells; Tumor Cells, Cultured | 1992 |
Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
Topics: Animals; Cell Hypoxia; Combined Modality Therapy; Drug Evaluation; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental | 1992 |
Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Female; Half-Life; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Prodrugs; Sarcoma, Experimental | 1991 |
Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
Topics: Administration, Oral; Animals; Combined Modality Therapy; Injections, Intraperitoneal; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental | 1991 |
Bioreductive drugs and the selective induction of tumour hypoxia.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Constriction; Hydralazine; Mice; Mice, Inbred C3H; Misonidazole; Mitomycin; Mitomycins; Radiation-Sensitizing Agents; Sarcoma, Experimental; Tirapazamine; Triazines | 1990 |
Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
Topics: Animals; Antineoplastic Agents; Female; Mice; Mice, Inbred C3H; Misonidazole; Prodrugs; Radiation-Sensitizing Agents; Sarcoma, Experimental | 1990 |
High uptake of RSU 1069 and its analogues melanotic melanomas.
Topics: Animals; Cell Line; Cell Membrane Permeability; Deoxyribonucleases; Drug Evaluation, Preclinical; Half-Life; Humans; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Microbial Collagenase; Misonidazole; Sarcoma, Experimental; Tissue Distribution; Trypsin; Tumor Cells, Cultured | 1989 |
Toxicity of RSU-1069 for KHT cells treated in vivo or in vitro: evidence for a diffusible toxic product.
Topics: Animals; Cell Count; Cell Survival; Diffusion; Male; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Oxygen; Radiation-Sensitizing Agents; Sarcoma, Experimental; Tumor Cells, Cultured | 1989 |
Chemosensitization of lomustine by misonidazole, benznidazole, and RSU 1069.
Topics: Animals; Lomustine; Mice; Mice, Inbred C3H; Misonidazole; Nitroimidazoles; Sarcoma, Experimental | 1986 |